Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ884MR)

This product GTTS-WQ884MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ884MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10552MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ5839MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ10047MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ2250MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ2905MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ12203MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ5040MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ10882MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MAb-14.18
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW